FDA Clearance Tracker · K150510
Total Bilirubin
Last checked: Nov 19, 2026Latest source record: Apr 2, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Apr 2, 2015
Substantially Equivalent
Time to decision
34 days
Received Feb 27, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K150510
- Device name
- Total Bilirubin
- Applicant
- Abbott Laboratories
- Applicant location
- Irving, TX
- Received
- Feb 27, 2015
- Decided
- Apr 2, 2015
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Diazo Colorimetry, Bilirubin (CIG)
- Device class
- Class II
- Regulation
- 21 CFR 862.1110
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CIG. The earliest in FDA's data is K760479, decided Oct 29, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K150510
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- Anti-HCV Next510(k)
K252424 · Decided Apr 28, 2026 · 270 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- ARCHITECT iGentamicin510(k)
K243500 · Decided Jul 9, 2025 · 239 days after receipt
Device type: Enzyme Immunoassay, Gentamicin (LCD) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.